Get the Stockscreener App
2.66
2.21%
-0.06
After Hours:
2.63
-0.03
-1.13%
Bioaffinity Technologies Inc stock is traded at $2.66, with a volume of 400.22K.
It is down -2.21% in the last 24 hours and down -67.16% over the past month.
bioAffinity Technologies Inc addresses the need for noninvasive diagnosis of early-stage cancer and diseases of the lung and targeted cancer treatment. It develops proprietary noninvasive diagnostic tests and cancer therapeutics using technology that preferentially targets cancer cells and cell populations indicative of a diseased state. The company's product, CyPath Lung, is a noninvasive test for the detection of early-stage lung cancer.
See More
Previous Close:
$2.72
Open:
$2.66
24h Volume:
400.22K
Relative Volume:
0.17
Market Cap:
$12.24M
Revenue:
$9.37M
Net Income/Loss:
$-8.45M
P/E Ratio:
-3.284
EPS:
-0.81
Net Cash Flow:
$-7.27M
1W Performance:
+3.91%
1M Performance:
-67.16%
6M Performance:
-83.58%
1Y Performance:
-95.36%
1-Day Range:
$2.56
$2.765
1-Week Range:
$2.41
$3.65
52-Week Range:
$2.3401
$67.12
Bioaffinity Technologies Inc Stock (BIAF) Company Profile
Name
Bioaffinity Technologies Inc
Sector
Industry
Phone
210-698-5334
Address
3300 NACOGDOCHES ROAD, SAN ANTONIO
Compare BIAF with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BIAF
Bioaffinity Technologies Inc
|
2.66 | 12.24M | 9.37M | -8.45M | -7.27M | -0.81 |
|
TMO
Thermo Fisher Scientific Inc
|
524.58 | 198.17B | 43.21B | 6.58B | 6.17B | 17.28 |
|
DHR
Danaher Corp
|
205.14 | 144.97B | 24.01B | 3.41B | 4.86B | 4.7082 |
|
IDXX
Idexx Laboratories Inc
|
633.32 | 49.29B | 4.04B | 985.66M | 774.34M | 12.01 |
|
A
Agilent Technologies Inc
|
138.23 | 38.73B | 6.79B | 1.22B | 1.09B | 4.2644 |
|
IQV
Iqvia Holdings Inc
|
203.77 | 33.69B | 15.70B | 1.24B | 2.01B | 6.9036 |
Bioaffinity Technologies Inc Stock (BIAF) Latest News
What recovery options are there for bioAffinity Technologies Inc.Trade Analysis Report & Growth Oriented Trade Recommendations - newser.com
Is bioAffinity Technologies Inc. Equity Warrant stock a good choice for value investorsJuly 2025 Reactions & High Accuracy Investment Signals - newser.com
Will bioAffinity Technologies Inc. stock deliver better than expected guidance2025 Big Picture & Long-Term Growth Stock Strategies - newser.com
Using data filters to optimize entry into bioAffinity Technologies Inc. Equity WarrantJuly 2025 PreEarnings & Fast Gaining Stock Reports - newser.com
Is it time to cut losses on bioAffinity Technologies Inc.Insider Selling & Accurate Buy Signal Alerts - newser.com
Will bioAffinity Technologies Inc. stock see insider buying2025 Market Sentiment & Free Community Supported Trade Ideas - newser.com
Will bioAffinity Technologies Inc. Equity Warrant benefit from macro trends2025 Sector Review & Accurate Entry/Exit Alerts - newser.com
Forecasting bioAffinity Technologies Inc. Equity Warrant price range with options dataWatch List & Verified Short-Term Plans - newser.com
Will bioAffinity Technologies Inc. stock maintain momentum in 2025Weekly Trend Report & Low Drawdown Investment Strategies - newser.com
Can trapped investors hope for a rebound in bioAffinity Technologies Inc. Equity WarrantWeekly Profit Analysis & Smart Allocation Stock Reports - newser.com
Intraday pattern recognizer results for bioAffinity Technologies Inc. Equity WarrantJuly 2025 Breakouts & AI Driven Stock Price Forecasts - newser.com
Will bioAffinity Technologies Inc. Equity Warrant stock beat EPS estimatesCEO Change & Smart Swing Trading Alerts - newser.com
How institutional buying supports bioAffinity Technologies Inc. Equity Warrant stockWeekly Stock Recap & Expert Verified Stock Movement Alerts - newser.com
Is bioAffinity Technologies Inc. building a consolidation baseQuarterly Portfolio Report & Real-Time Buy Zone Alerts - newser.com
Is bioAffinity Technologies Inc. Equity Warrant stock attractive for retirement portfoliosJuly 2025 Highlights & AI Based Buy/Sell Signal Reports - newser.com
Key resistance and support levels for bioAffinity Technologies Inc. Equity WarrantTake Profit & Fast Entry High Yield Tips - newser.com
Analyzing bioAffinity Technologies Inc. with multi timeframe chartsQuarterly Portfolio Review & Fast Gaining Stock Reports - newser.com
Biotech Stocks To Follow TodayOctober 8th - MarketBeat
How to track smart money flows in bioAffinity Technologies Inc. Equity WarrantVolume Spike & Reliable Entry Point Alerts - newser.com
Visual trend scoring systems applied to bioAffinity Technologies Inc. Equity WarrantJuly 2025 Volume & Trade Opportunity Analysis - newser.com
Developing predictive dashboards with bioAffinity Technologies Inc. data2025 Analyst Calls & Weekly High Momentum Picks - newser.com
bioAffinity Technologies Announces $1.8M Direct Offering - MSN
bioAffinity Technologies, Inc. Announces Closing of $1.8 Million Registered Direct Financing of Comm - PharmiWeb.com
$1.8M Registered Direct Offering: bioAffinity Closes 720K Shares to Fund CyPath Lung Sales - Stock Titan
bioAffinity Technologies closes $1.8 million registered direct offering - Investing.com India
BioAffinity Technologies Closes $1.8 Million Registered Direct Offering - MarketScreener
bioAffinity Technologies, Inc. Announces Closing of $1.8 Million Registered Direct Financing of Common Stock Priced At-The-Market Under Nasdaq Rules - Business Wire
What analysts say about bioAffinity Technologies Inc stockLong-Term Growth Stocks & Affordable Portfolio Growth - earlytimes.in
Can trapped investors hope for a rebound in bioAffinity Technologies Inc.2025 Buyback Activity & Reliable Entry Point Alerts - newser.com
Exit strategy if you’re trapped in bioAffinity Technologies Inc.Gap Up & Low Risk Entry Point Guides - newser.com
Does bioAffinity Technologies Inc. Equity Warrant fit your quant trading modelWeekly Trend Recap & Stock Portfolio Risk Control - newser.com
How to build a dashboard for bioAffinity Technologies Inc. stockTrade Risk Report & Long-Term Safe Return Strategies - newser.com
Signal strength of bioAffinity Technologies Inc. stock in tech scannersWeekly Trend Summary & AI Enhanced Market Trend Forecasts - newser.com
Why bioAffinity Technologies Inc. stock appeals to analystsQuarterly Profit Report & Daily Growth Stock Tips - newser.com
How to read the order book for bioAffinity Technologies Inc.July 2025 Levels & Low Drawdown Momentum Ideas - newser.com
BioAffinity Technologies Launches $1.8 Million Registered Direct Offering - MarketScreener
bioAffinity Technologies raises $1.8 million in direct offering By Investing.com - Investing.com Nigeria
bioAffinity Technologies raises $1.8 million in registered direct offering By Investing.com - Investing.com Nigeria
WallachBeth Capital announces bioaffinity technologies - MarketScreener
bioAffinity Technologies raises $1.8 million in registered direct offering - Investing.com India
WallachBeth Capital Announces bioAffinity Technologies Approximately $1.8 Million Registered Direct Financing of Common Stock Priced At-The-Market Under Nasdaq Rules - cnhinews.com
bioAffinity Technologies raises $1.8 million in direct offering - Investing.com
BioAffinity Technologies announces $1.8M registered direct offering - TipRanks
bioAffinity Technologies, Inc. Announces Approximately $1.8 Million Registered Direct Financing of Common Stock Priced At-The-Market Under Nasdaq Rules - The Joplin Globe
$1.8M registered direct raise — bioAffinity to sell 720K shares to fund CyPath Lung sales - Stock Titan
BioAffinity Technologies Stock Surges: What’s Next? - StocksToTrade
What's Driving bioAffinity Technologies' Big Pre-Market Surge? - Benzinga
bioAffinity Technologies Reports Record Growth in CyPath® Lung Test Volume for Third Quarter 2025 - BioSpace
bioAffinity Technologies reports 95% quarterly sales growth for lung test By Investing.com - Investing.com Canada
bioAffinity Technologies Reports 95% Sales Surge in Q3 2025 - TipRanks
BioAffinity's lung cancer test sales soar 95% as veterans' hospitals drive adoption - The Business Journals
Bioaffinity Technologies Inc Stock (BIAF) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.61%
0.70%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):